| Description |
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice[1].
|
| Related Catalog |
|
| Target |
hCB2-R
|
| In Vitro |
SCH 336 (Sch.336) (0-10 µM) competes with [3H]CP55,940 for binding to human CB2 on Sf9 cell membranes with Ki of 1.8 nM, and decreases GTPγS binding on human CB2-containing membranes with an EC50 of 2 nM, decreases potency on CB1-containing membranes with EC50 of 200 nM[1]. SCH 336 inhibits BaF3/CB2 migration to 100 nM 2-AG with an IC50 of 34 nM[1].
|
| In Vivo |
SCH 336 (0.02, 0.2, 2.0 mg/kg; i.p.) significantly inhibits the migration of leukocytes[1]. Animal Model: Female B6D2/F1 mice (HU210)[1] Dosage: 0.02, 0.2, 2.0 mg/kg Administration: I.p. Result: Significantly inhibited the migration of leukocytes into the CCL2-soaked gel foam sponge.
|
| References |
[1]. Lunn CA, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8.
|
